NSD3 and hematopoietic and lymphoid cell neoplasm: MS9715 effectively inhibited NSD3-dependent hematological cancer cells and suppressed NSD3- and cMyc-driven oncogenic pathways more effectively than BI-9321 alone, recapitulating the effects of NSD3 knockout [65].